PlatformPlatform overviewCOA reviewSupplier document collectionSupplier follow-up (Vera)Supplier qualificationRelease workflowsMock inspections (Cato)Chain of custodyPatient traceabilityUnit-level traceabilityPartner RecordAPIPricing
SolutionsCompounding pharmacies503B outsourcing facilitiesClinicsMed spasTelehealth platformsConsultantsSolutions overview
ResourcesMethodologyOrder-level COA traceabilitySupplier packet diligenceResource libraryPublic toolsIntelligenceTrust Center
CompanyAbout VerituraWhy independentPartnersFor counselContact
Sign inGet a demo

Your next FDA letter, written early

Telehealth: your website, read the way the FDA's warning letters read it.

Send us your company's web address. Within one business day you get one document: every sentence that matches a claim type the FDA has cited in its warning letters to telehealth companies, with the FDA's own reason and a corrected sentence beside it, and the public record of each pharmacy we can identify. Everything in it is public, so you send nothing but the address. It is free.

You send one addressYour company's public website. A photo of one vial label is optional, with no patient's name on it.
You get one documentEach matching sentence, the FDA's reason in its own words, a corrected sentence, and each pharmacy's public record.
Within one business dayPrepared by hand at Veritura. It is free.

What you get

Your sentences beside the sentences the FDA has cited.

The pictures show the same review on Northway Health, a sample telehealth platform on the demo workspace. Its pages, partners and figures are invented.

  1. Every sentence that matches a cited claim type.

    We set the sentences on your public pages against 17 claim types drawn from the FDA's warning letters to telehealth companies. For each match: the claim type, how many letters cited it, what the FDA said was wrong in its own words, and a corrected sentence beside it.

    • A fact we do not have, such as the pharmacy's name, shows in square brackets, never guessed
    • "FDA-registered" alone is marked as a caution: no letter has cited it by itself
    • No match says only that no sentence matched
  2. What your label names.

    If you send a photo of a vial label, we say whether it names your brand, the pharmacy that compounded the drug, or both. 52 of the 114 letters cite a label that names the brand and not the pharmacy that compounded the drug. With no photo, this part is left out, and the document says so.

    • The FDA's reason: "suggesting [brand] is the compounder... when in fact it is not"
    • One label from each pharmacy you name is enough
    • Cover any patient's name before you send it

Three of the 17 claim types

The type, how many letters cited it, and the FDA's reason.

Veritura's count of the FDA's posted warning letters to telehealth companies, September 2025 to October 2026. One letter can cite several types.

114 letters
  • Every letter the FDA's database tags Telehealth, dated September 9, 2025 to October 30, 2026
Sameness to the brand-name drug: 58
  • "Your claims imply that your products are the same as an FDA-approved product when they are not."
Clinical proof: 26
  • "Overstatements of efficacy or minimization of risk are of particular concern."
The pharmacy said to be licensed or backed by the FDA: 13
  • "are not 'FDA-approved' or 'FDA-licensed' entities"

The pharmacies behind your products

The public record of each pharmacy we can identify.

For each pharmacy your website or your label names, its state license and the FDA's records of inspections, warning letters and recalls, each with its source and the date we looked. A pharmacy we cannot identify from public pages is listed as not identified. An FDA warning letter to a telehealth company, June 2026, asks the firm to respond "within fifteen (15) business days of receipt of this letter", and names among the steps a response may include "Identifying the entities that produce the compounded drug products offered on your website". Read on the FDA's warning letters page on November 17, 2026.

What we need from you.

Your web address

The public site where you offer compounded drugs. We read its pages as they stand on the day.

A label photo, if you like

One vial label from each pharmacy, with no patient's name on it. Without it, the label part is left out.

Nothing else

No account, no orders and no patient data. Everything in the document is public.

What it is not

We review documents. We do not test material.

Not a promise about letters

It says which sentences match a claim type the FDA has cited. It never says that no letter will come.

Not advice about any law

It sets your words beside the FDA's. What you change is your decision.

Not a review of your ads

It reads your public web pages on the day. It does not read ads.

Questions telehealth companies ask.

What does it cost?

Nothing. The claims review of your website is free, and you send nothing but the address.

If no sentence matches, are we clear?

No. A page with no match says only that no sentence matched one of the 17 claim types. It says nothing about whether a letter will come, and we never promise that none comes.

Where do the claim types come from?

From the FDA's posted warning letters to telehealth companies, September 2025 to October 2026, as Veritura counted them: 114 letters, coded by the claim each one quotes. Each type keeps the FDA's stated reason, in its own words.

What happens after we get it?

The document is yours to keep. The same review runs in the Veritura workspace for telehealth platforms, where each saved page is reviewed again every week. See the telehealth page.

Send one COA you already hold.

We review it with you, free. You leave with every finding documented and the request to your supplier written.

Drop a COA you already haveEach finding cites the line it came from and the requirement it was checked against.Review it free